A foot drop correcting FES envelope design method using tibialis anterior EMG during healthy gait with a new walking speed control strategy

Restoring walking functions will greatly improve the foot-drop patients' life quality. In this work, we sampled 10 healthy subjects' gait data when walking in 4 different stride frequency overground and developed a dynamic Functional Electrical Stimulation (dFES) system for foot-drop patients' walk training, using the processed tibialis anterior (TA) muscle EMG signal. The data sampled under the new strategy can be used by FES system directly. And the dFES system can provide dynamic Pulse Width Modulation (PWM) FES serial according to the healthy subjects' TA EMG intensity features.

Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis

Hypoxia-inducible factor-1alpha (HIF-1alpha) is a main responder to intracellular hypoxia and is overexpressed in many human cancers, including renal cell carcinoma (RCC). To better understanding of the role of HIF-1alpha in the tumorigenicity of RCC, we used short-hairpin RNA (shRNA) interference to inhibit HIF-1alpha expression in the human renal cancer cell line, Caki-1 and OS-RC-2. Silencing of HIF-1alpha significantly reduced the expression of HIF-1alpha in both of renal cancer cell lines. In vitro downregulation of HIF-1alpha inhibited Caki-1 and OS-RC-2 cell growth, migration and invasion. The results further showed that HIF-1alpha silencing resulted in caspase-dependent apoptosis of Caki-1 and OS-RC-2 through regulation of PI3K/Akt pathway and Bcl-2-related proteins expression. In vivo animal studies showed that tumor growth was significantly inhibited in HIF-1alpha shRNA-transfected RCC. Intratumor gene therapy with polyethylenimine-loaded HIF-1alpha shRNA also resulted in tumor growth suppression. Thus, this study demonstrates that downregulation of HIF-1alpha could suppress tumorigenicity of RCC through induction of apoptosis, and HIF-1alpha shRNA may be a promising strategy for the treatment of RCC.

Onyx migration in the endovascular management of intracranial dural arteriovenous fistulas

Onyx migration in the endovascular treatment of dural arteriovenous fistulas (dural AVFs) is uncommon. We describe five cases of Onyx migration to the heart and draining vein and its avoidance. Between February 2007 and August 2008, Onyx migration was encountered in five patients with dural AVFs treated endovascularly at our institute. Procedures performed under general anesthesia consisted of two arterial approaches and three venous approaches. Two patients with dural AVFs involving the transverse-sigmoid sinus were treated by transarterial embolization using Onyx-18 via the occipital artery and the posterior branch of the middle meningeal artery, respectively. A piece of Onyx was found in the right ventricle on post-embolization chest X-ray film in both patients, one developed tricuspid valve dysfunction requiring thoracic surgery and one was asymptomatic. The other three patients were treated with a combination of Onyx (34 or 18) and coils transvenously with venous Onyx migration leading to draining vein occlusion, one with dural AVF involving the tentorium died from venous rupture, two patients with bilateral dural AVFs of the cavernous sinus (one with deterioration of ocular symptoms and one without symptoms). Postoperative digital subtraction angiography confirmed the elimination of dural AVF in one patient, and residual fistulae in three patients. The follow-up study ranging from two to nine months (average, 4.5 months). Three patients recovered to their full activities, while one had visual disturbance. Although Onyx has been considered a controllable embolic agent, its migration to other locations causing clinical deterioration can occur. This problem should be noted and prevented.

Condylomata gigantea in a male transsexual

Summary

As the incidence of genital warts increases, warts arising in the mouth, throat and other sites can occasionally be seen. Condyloma gigantea in genital sites are often reported, but literature on genital warts in transsexuals is rare. We present a case of C. gigantea in a 23-year-old male-to-female transsexual, whose warts arose on the transplanted skin of a neovagina and in the perianal region. We conclude that although C. gigantea can occur in transsexuals, the best way to treat it is not clear.

Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice

To characterize the changes in osteoprotegerin-deficient (OPG-/-) mice mandibles and the possible mandibular bone loss prevention by zoledronate. This preventive effect in the mandible differed from that in the proximal tibia and was independent of the OPG pathway.

INTRODUCTION

The study aimed to characterize both the changes in the mandible in osteoprotegerin-deficient (OPG-/-) mice and possible mandibular bone loss prevention by zoledronate.

METHODS

Twenty-eight 6-week-old female mice (C57BL/6J), including OPG-/- (n = 21) and wild-type (WT) (n = 7) mice, were assigned to four groups after 2 weeks of acclimatization to local vivarium conditions: wild mice with vehicle (WT group); OPG-/- mice with vehicle (OPG-/- group); and OPG-/- mice that were subcutaneously injected with either 50 or 150 microg/kg zoledronate (Zol-50 and Zol-150 groups, respectively). Mice were sacrificed at 4 weeks after these treatments and after fasting for 12 h. Sera were harvested for biochemical analyses. The right mandible and tibia of each mouse were selected for microCT analysis. Student's t-test was performed for comparisons of bone parameters at different sites in the WT group. Analysis of variance (ANOVA) was used to compare the biomarkers and bone parameters in the different treatment groups.

RESULTS

Serum bone-specific alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRACP-5b) were significantly decreased in WT mice as compared to the levels in the OPG-/- mice (P < 0.05). Zoledronate treatment decreased the high serum B-ALP activity observed in OPG-/- mice to the levels seen in WT mice, while serum TRACP-5b concentrations were decreased to levels even lower than those in WT mice. There were substantial variations in BMD and microstructure of the mandibular and proximal tibial trabeculae. Mandibular bone loss was less affected by OPG gene deprivation than the proximal tibia was. Both zoledronate groups showed greater BMD, trabecular BV/TV, Tb.Th, Tb.N, and Conn.D and a significant decrease in Tb.Sp and SMI as compared to the findings in OPG-/- mice (P < 0.05). However, higher apparent BMD and more compact plate-like trabeculae were observed in the mandible after treatment with zoledronate as compared to the findings in the proximal tibia. No significant differences were found in any parameter in both zoledronate groups.

CONCLUSIONS

The present study showed that zoledronate could reverse the significant bone loss in mice mandibles that was induced by OPG gene deficiency. This preventive effect, which was accompanied with considerable inhibition of bone turnover, differed in the mandible and in the proximal tibia and was independent of the OPG pathway.

Stability of hydrophilic magnetic nanoparticles under biologically relevant conditions

Hydrophilic 2,3-dimercaptosuccinnic acid (HOOC-CH(SH)-CH(SH)-COOH, DMSA) coated monodisperse magnetic nanoparticles (Fe3O4) were dispersed in water, RPMI-1640 with 10% (v/v) fetal calf serum, RPMI-1640, PBS and MES, respectively, to investigate their stability under biologically relevant conditions. The Photon Correlation Spectroscopy (PCS) results showed that DMSA-Fe3O4 nanoparticles existed as aggregate under biological conditions. UV-vis, MRI and AFM results indicated that DMSA-Fe3O4 nanoparticles dispersed in RPMI-1640, PBS and MES presented poor stability, whereas those dispersed in RPMI-1640 with fetal calf serum exhibited excellent stability, which was due to their adsorption from fetal calf serum, as confirmed by zeta potential and IR results. Additionally, in vitro cell experiments showed that DMSA-Fe3O4 nanoparticles with adsorption from fetal calf serum had higher intracellular uptake than those without adsorption from serum, indicating that fetal calf serum could play a great role in intracellular uptake of nanoparticles.

Statins decrease the aberrant HLA-DR expression on thyrocytes from patients with Hashimoto's thyroiditis

Statins have been found to exert anti-inflammatory and immune modulatory effects. It seems likely that these drugs may improve thyroid function in patients with Hashimoto's thyroiditis (HT). The objective of our study was to investigate the effect of statins on HLA-DR (human leukocyte antigen D-related) expression of thyrocytes from patients with HT hypothyroidism. Thyroid tissues were obtained from surgical specimens. Thyrocytes were cultured in the presence or absence of IFN-gamma (50 ng/ml) with or without statins (simvastatin 10 microM or atorvastatin 10 microM) for 72 hours. HLA-DR expression was detected by flow cytometry. Normal thyrocytes were used for controls. HLA-DR expression of HT thyrocytes was much higher than that of normal thyrocytes (41.2+/-4.5% vs. 2.7+/-2.1%, p<0.01), which could be further increased by IFN-gamma stimulation in both groups (p<0.01). However, simvastatin and atorvastatin could significantly inhibit the "aberrant" HLA-DR expression on HT thyrocytes and decrease IFN-gamma- induced HLA-DR expression in both HT and normal thyroid cells (p<0.01). Statins can repress HLA-DR expression of HT thyrocytes, which might inhibit the subsequent lymphocyte activation and ameliorate the immune disturbance of HT.

Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes

Visfatin is an independent association factor for type 2 diabetes mellitus (T2DM). In order to evaluate the plasma visfatin levels and investigate whether plasma visfatin concentrations are altered by intensive glycemic control in patients with diabetes, we determined plasma visfatin concentrations and metabolic parameters in 53 newly diagnosed type 2 diabetic patients and 35 healthy controls. Visfatin levels were also investigated before and after intensive glycemic control for three months in subgroup of patients with T2DM. Plasma visfatin levels were significantly elevated in diabetic patients compared with healthy controls (p<0.001). Circulating visfatin concentration was associated with fasting plasma glucose (FPG), 2-hour OGTT plasma glucose (2hPG), HOMA-beta indexes (r=0.338, p=0.001; r=0.340, p=0.002; r=-0.296, p=0.006, respectively), but not with insulin sensitivity (HOMA-IR) or other metabolic or anthropometric parameters in all subjects. In addition, visfatin levels were also correlated with HbA1c levels in diabetic patients. Furthermore, visfatin concentrations reduced from 25.0+/-6.5 ng/ml at baseline to 20.3+/-4.7 ng/ml (p<0.01) after 3 months of intensive glycemic control, while HbA1c levels decreased from 9.0+/-1.8% to 6.2+/-0.7% (p<0.01). We conclude that the change of visfatin concentration may be a compensatory mechanism to ameliorate insulin deficiency due to pancreatic beta-cell dysfunction.

Interferon gamma receptor 1 gene polymorphism in patients with tuberculosis in China

The aim of the study was to examine the influence of the CA microsatellite polymorphisms of interferon gamma receptor 1 on patients with tuberculosis (TB) in the south-eastern Chinese population. Genomic DNA from patients with TB (n = 155) and ethnically matched controls (n = 89) were genotyped by short tandem repeat-PCR method. The allele frequency of (CA)(25) was 1.70-fold higher among patients than that among controls (95% CI 1.07-2.70) (P = 0.025). Compared with the non-(CA)(25)/non-(CA)(25) reference group, the risk to TB of the carriers of (CA)(25)/(CA)(25) genotypes were 6.46-fold (95% CI 1.40-29.74) (P = 0.0017) higher. On the contrary, the allele frequency of (CA)(26) was 0.29-fold lower in patients than that in controls (95% CI 0.11-0.76) (P = 0.012). Genotypes with (CA)(26) allele were at 0.35-fold (95% CI 0.13-0.98) (P = 0.045) lower to the risk of TB, compared with that of the non-(CA)(26)/non-(CA)(26) in the reference group. The above results indicated that the allele (CA)(25) appeared to be susceptible to TB, while the allele (CA)(26) to be protective towards TB. Our data also suggest that the CA repeat was a highly polymorphic marker and could be used for linkage and association analysis.

Circulating chemokines in patients with autoimmune thyroid diseases

Chemokines are a group of small proteins that recruit different leukocyte subtypes to sites of inflammation and play important roles in initiating and maintaining immunological responses in autoimmune endocrine diseases including Graves' disease (GD) and Hashimoto's thyroiditis (HT). Previous studies have found increased gene and protein expression of different kinds of chemokines not only within the thyroid gland but also within thyroid cells in GD or HT patients. A few studies have determined serum levels of chemokines, with conflicting results. We measured circulating concentrations of CCL2, CCL5, CXCL9, and CXCL10 in patients with GD, HT, and nontoxic nodular thyroid disease (NNT). While CCL2 and CXCL9 concentrations were comparable in patients with either AITD or NNT, CCL5 was significantly increased in GD patients compared with HT or NNT subjects. In contrast, CXCL10 levels were lower in patients with GD, but the difference was statistically significant only when compared with patients with HT (p=0.0018). Importantly, GD patients who relapsed or went into remission had significantly different levels of CXCL9 (p=0.0252). Serum levels of CCL2, CCL5, CXCL9, and CXCL10 did not reveal any correlation with thyroid volume; with the levels of thyrotropin (TSH), FT3, or FT4; or with the titers of TSH receptor antibody and thyroperoxidase antibody. These data suggest that the expression patterns of chemokines in various thyroid diseases differ from each other, which may reflect the distinct immune responses in HT and GD.